Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Broadening Access to Continuous Glucose Monitoring for Patients With Type 2 Diabetes

Broadening Access to Continuous Glucose Monitoring for Patients With Type 2 Diabetes Opinion EDITORIAL Broadening Access to Continuous Glucose Monitoring for Patients With Type 2 Diabetes Monica E. Peek, MD, MPH, MS; Celeste C. Thomas, MD, MS Persons from racial and ethnic minority populations, those in was 3.6 hours per day higher, the mean glucose level was low-income groups, and other socially marginalized groups are 26 mg/dL lower (95% CI, −41 to −12), and the time with glu- cose levels greater than 250 mg/dL was 3.8 hours per day less disproportionately affected by type 2 diabetes and experience higher disease prevalence, poorer glycemic control, higher rates in the CGM group (all P < .001). There were also high rates of of diabetes complications, and satisfaction among CGM users. higher prevalence of comor- Karter et al conducted a retrospective cohort study of Related articles pages 2273 1,2 bid conditions. Achieving 41 753 adult patients (36 080 with type 2 diabetes, 5673 with and 2262 glucose targets that will re- type 1 diabetes) who were treated with insulin and were re- duce the risk of diabetes complications, particularly among high- ceiving care at Kaiser Permanente. The authors followed the risk groups, is critical to improve the health and well-being of outcomes of those http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Broadening Access to Continuous Glucose Monitoring for Patients With Type 2 Diabetes

JAMA , Volume 325 (22) – Jun 8, 2021

Loading next page...
 
/lp/american-medical-association/broadening-access-to-continuous-glucose-monitoring-for-patients-with-RW0Yyelo5e
Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.6208
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Broadening Access to Continuous Glucose Monitoring for Patients With Type 2 Diabetes Monica E. Peek, MD, MPH, MS; Celeste C. Thomas, MD, MS Persons from racial and ethnic minority populations, those in was 3.6 hours per day higher, the mean glucose level was low-income groups, and other socially marginalized groups are 26 mg/dL lower (95% CI, −41 to −12), and the time with glu- cose levels greater than 250 mg/dL was 3.8 hours per day less disproportionately affected by type 2 diabetes and experience higher disease prevalence, poorer glycemic control, higher rates in the CGM group (all P < .001). There were also high rates of of diabetes complications, and satisfaction among CGM users. higher prevalence of comor- Karter et al conducted a retrospective cohort study of Related articles pages 2273 1,2 bid conditions. Achieving 41 753 adult patients (36 080 with type 2 diabetes, 5673 with and 2262 glucose targets that will re- type 1 diabetes) who were treated with insulin and were re- duce the risk of diabetes complications, particularly among high- ceiving care at Kaiser Permanente. The authors followed the risk groups, is critical to improve the health and well-being of outcomes of those

Journal

JAMAAmerican Medical Association

Published: Jun 8, 2021

References